Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$17.35B
Positions
101
New
9
Increased
16
Decreased
12
Sold Out
15
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $17.35B across 101 positions in their Q3 2023 SEC 13F filing (period ending 2023-09-30). The top 10 positions account for 90.2% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | $9.45B | 54.48% | - |
| 2 | ONCBeiGene, Ltd. | $2.10B | 12.10% | - |
| 3 | INCYIncyte Corporation | $2.09B | 12.05% | +0.0% |
| 4 | ACADACADIA Pharmaceuticals Inc. | $893.30M | 5.15% | - |
| 5 | BMRNBioMarin Pharmaceutical Inc. | $337.13M | 1.94% | - |
| 6 | MDGLMadrigal Pharmaceuticals, Inc. | $225.65M | 1.30% | - |
| 7 | RYTMRhythm Pharmaceuticals, Inc. | $153.65M | 0.89% | +3.1% |
| 8 | ROIVRoivant Sciences Ltd. | $138.73M | 0.80% | +26.0% |
| 9 | IMCRImmunocore Holdings plc | $130.83M | 0.75% | - |
| 10 | Invitae Corporation | $130.37M | 0.75% | - |
| Stock | Value | Shares |
|---|---|---|
| IMVTImmunovant, Inc. | $16.32M | 425,009 |
| ARVNArvinas, Inc. | $8.12M | 413,481 |
| TSHATaysha Gene Therapies, Inc. | $7.92M | 2,504,756 |
| SGMTSagimet Biosciences Inc. | $7.18M | 815,359 |
| NVTA 4.5 03/15/28 AInvitae Corporation | $6.21M | 9,274,000 |
| MIRMMirum Pharmaceuticals, Inc. | $6.02M | 190,476 |
| MORFUSDMorphic Holding, Inc. | $4.94M | 215,800 |
| CELCCelcuity Inc. | $4.89M | 535,478 |
| Neoleukin Therapeutics, Inc. | $4.82M | 1,221,414 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.